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Poster Session II S375Materials andMethods:Three humanMSCs cultures fromdifferent
healthy donors & 5 neuroblastoma cell lines (BE2c, BE2M17, IMR32,
SK-N-LP and SH-SY5Y) originally derived frommetastatic sites were
used. ELISA was used to determine the concentration of SDF-1 re-
leased by MSCs in conditioned culture medium. CXCR4 and
CXCR7 expression on neuroblastoma cells was determined by flow cy-
tometer. shRNA plasmid transfection was used to establish stable
CXCR4 andCXCR7 knockdown IMR32 cell lines and assessed the re-
spective functionsof these two receptorsonneuroblastomacells.Trans-
well migration assay, invasion and adhesion assays were utilized to test
the migration, invasion and adhesion efficiency of normal or knock-
down neuroblastoma cells towards MSCs under the influence of
MSCs conditionedmedium, SDF-1 or AMD3100 (CXCR4 inhibitor).
Results: SDF-1 was secreted by all human bone marrow derived
MSCs. CXCR4 and CXCR7 were expressed on neuroblastoma cells
surface. Themigration of IMR32, SK-N-LP and SH-SY5Ywas dra-
matically enhanced under treatments with culture medium from
MSCs. The migration ability of CXCR4 knock down (IMR32-sh-
CXCR4) but not CXCR7 knock down (IMR32-sh-CXCR7) was
partially blocked under culture medium of MSCs and SDF-1. In
contrary, all migration could be blocked by AMD3100. The invasion
ability of IMR32-sh-CXCR4 but not IMR32-sh-CXCR7 was sup-
pressed when treated with either culture medium of MSCs or
SDF-1. All invasion activity could be blocked byAMD3100, suggest-
ing such effect was associated with SDF-1/CXCR4 axis.
Conclusion: Our data suggested that: 1) SDF-1 was secreted by
MSCs; 2) metastatic neuroblastoma cell lines expressed both
CXCR4 and CXCR7, and the interactions of these receptors with
SDF-1 secreted by MSCs may play an important role in the migra-
tion, invasion but not adhesion in the metastasis of neuroblastoma
to bone marrow.PHARMACY465
PHARMACOECONOMIC ANALYSIS OF EARLY VS. DELAYED INITIATION OF
G-CSF SUPPORT FOLLOWING HSCT
Kim, S.S.1, Isola, L.2, Grosskreutz, C.2, Kim, J.E.3 1The Mount Sinai
Medical Center, New York, NY; 2The Mount Sinai Medical Center,
New York, NY; 3Montefiore Medical Center, Bronx, NY
Granulocyte colony stimulating factor (G-CSF) has been widely
used to accelerate neutrophil recovery following hematopoietic
stem cell transplantation (HSCT). BMT practice has shifted from
introducing G-CSF immediately after HSCT to delaying its initia-
tion until 5-7 days after the HSCT. The primary reason for this
change in practice is not only for pharmacoeconomic consideration,
but also for its preferential pharmacologic effect as it takes about 7
days for immature pluripotent stem cells to differentiate into highly
G-CSF responsible neutrophilic progenitor cells. In April 2010, we
implemented a practice change from initiating G-CSF support from
day 0 (immediately after stem cell infusion) to day +5 for autologous
SCT (ASCT) and day +7 for allogeneic SCT (AlloSCT).
A single-center retrospective study was performed, between Janu-
ary 2010 to August 2010, in a total of 60 patients who received G-
CSF support followingHSCT; of these patients, 30 patients received
early G-CSF and 30 patients received delayed G-CSF. G-CSF ther-
apy was administered intravenously at a dosage of 5mcg/kg/day. Pri-
mary objective of the study was to assess cost analysis of early and
delayed G-CSF therapy in patients who underwent HSCT.
Comparedwith the early G-CSF group, delayedG-CSF group re-
quired fewer number of G-CSF doses per patient (median, 7 doses
vs. 13 doses, p\0.001). The median acquisition cost of G-CSF per
patient was $3,300 in the early G-CSF group and $1,800 in the de-
layed G-CSF group, with total cost savings of $240,000 per year.
The median time to neutrophil engraftment in the early G-CSF
group was a day shorter compared to delayed G-CSF group (11
days vs. 12 days; p\0.05). However, there were no differences be-
tween the early and delayed G-CSF groups in the median duration
of neutropenia (6.5 days vs. 7 days; p 5 NS), rate of febrile neutro-
penia (60.9% vs. 54.1%; p5NS), median duration of febrile neutro-
penia (1 day vs. 1 day; p 5 NS), and median length of hospital stay
(15.5 days vs.15 days; p 5 NS).Delaying G-CSF support from day 0 to day +5 for ASCT and day
+7 for AlloSCT is a cost-effective strategy inHSCTpatients without
any significant impact on the duration of neutropenia and/or dura-
tion of hospitalization.
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STANDARDIZATION OF MELPHALAN ADMINISTRATION
Davis, D., Shapiro, J., Wetzstein, G. Moffitt Cancer Center, Tampa, FL
Over the past several years drug shortages have become a larger
problem for hospitals, medical professionals and ultimately a crisis
for patients who are directly affected. The American Hospital Asso-
ciation reports that 82% of their members this year have been af-
fected by some form of drug shortage. As of September 2011 the
FDA currently reports 71 medications listed as shortage status.
Melphalan is a very potent alkylating chemotherapy agent that is
part of conditioning chemotherapy for patients with either multiple
myeloma who will have a high-dose melphalan regimen or lym-
phoma patients receiving the BEAM regimen (BCNU, etoposide,
cytarabine, melphalan) prior to undergoing an autologous stem
cell transplant. Melphalan is unique in that it has an extremely short
stability requiring rapid administration after preparation. Preparing
this medication in a timely fashion is essential for drug efficacy and
can be burdensome for nursing and pharmacy staff.
In order to prevent medication shortages and reduce preparation
redundancies, the BMTpharmacists developed a plan to improve co-
ordination and efficiency of melphalan utilization. This was accom-
plished by standardizing times of administration for melphalan to
only be administered twice a day. This involved process changes
for BMT nursing and pharmacy. The nurses in BMT would give
the clinical leader the ok to proceed with chemotherapy. Once all pa-
tients were given the ok to proceed the floor clinical leader would
contact the pharmacist to make the chemotherapy immediately.
This process change went into effect October 19th, 2010 at Moffitt
Cancer Center.
This process change was retrospectively evaluated from January 1
to August 31, 2011. During this time period, 52 vials of melphalan
were saved which resulted in a cost savings of $88,137 in drug cost
alone and no patients were affected in May 2011 during a temporary
melphalan drug shortage.
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OBSERVATIONAL STUDY OF TACROLIMUS-INDUCED POSTERIOR RE-
VERSIBLE ENCEPHALOPATHY SYNDROME IN ALLOGENEIC STEM CELL
TRANSPLANTATION
Hammerstrom, A.E.1, Howell, J.E.1, Gulbis, A.M.1, Wilhelm, K.L.1,
Hart, J.W.1, Popat, U.R.2 1University of Texas MD Anderson Cancer
Center, Houston, TX; 2University of Texas MDAnderson Cancer Center,
Houston, TX
Objectives: Tacrolimus-induced posterior reversible encephalopa-
thy syndrome (PRES) is a potential complication of allogeneic hema-
topoietic stem cell transplantation (HSCT). Due to the paucity of
information on the management of PRES in HSCT patients receiv-
ing tacrolimus, this retrospective review will provide information on
trends associated with the incidence of PRES and characterize its
management.
Methods: A retrospective review was conducted of patients receiv-
ing tacrolimus for prevention of graft versus host disease (GVHD)
after allogeneic HSCT who developed PRES from 2008 to 2010 at
the University of Texas MD Anderson Cancer Center. Patients
were included if they were receiving tacrolimus at time of PRES di-
agnosis.
Results: Sixteen patients were identified as having PRES. Compared
to baseline, patients with PRES were likely to have an increase in
mean arterial pressure (MAP), weight, and serum creatinine. Ele-
vated tacrolimus levels and hypomagnesemia were not clearly ob-
served with PRES onset. When tacrolimus was held and then
restarted either at the same dose or targeting a lower therapeutic
level (n 5 9), 44% were alive at discharge. Of the patients switched
to another agent at time of PRES (n 5 2), 50% were alive at dis-
charge. In those patients in which tacrolimus was never held (n 5
5), 20% were alive at discharge.
Conclusions: The incidence of PRES at our institution from 2008-
2010 was 1.1%. A lower chance of survival was observed when tacro-
limus was never held during the PRES episode compared to the
S376 Poster Session IIother management strategies. Associated increases in MAP, weight,
and serum creatinine at the time of PRES compared to baselinemea-
surements exemplify the importance of possible prevention through
more aggressive blood pressure and fluid management strategies in
this patient population.
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A COMPARISON OF CALCULATED GLOMERULAR FILTRATION RATE (GFR)
VS. MEASURED GFR IN A BLOOD AND MARROW TRANSPLANT POPULA-
TION
Shapiro, J.F.1, Ho, V.1, Wetzstein, G.1, Woodard, A.1, Rawal, B.2,
Pidala, J.3 1H. Lee Moffitt Cancer Center, Tampa, FL; 2H. Lee Moffitt
Cancer Center, Tampa, FL; 3H. Lee Moffitt Cancer Center, Tampa, FL
One of the most controversial topics in clinical practice is the es-
timation of a patient’s creatinine clearance (CrCl) and determination
of renal function. The gold standard in determining the glomerular
filtration rate (GFR) involves a 24 hour urine collection, which can
be onerous to patients and potentially inaccurate. As a result, the
most common method to determine GFR utilizes the Cockcroft-
Gault equation (CG) and Modification of Diet in Renal Disease
(MDRD) equation. One limitation with the CG equation is the de-
bate regarding which weight should be utilized.
Up until January 2010, a 24 hr collected CrCl was standard prac-
tice at Moffitt Cancer Center (MCC) for patients undergoing hema-
topoietic cell transplant (HCT) to assess patients’ renal function.
Because of the potential concerns with the collected 24 hour CrCl,
the department decided to calculate GFR utilizing the CG equation.
We performed a retrospective analysis to assess whether calculated
CrCl using actual, adjusted, or ideal bodyweight best correlated with
CrCldeterminedby 24hoururine collection.TheHCTdatabasewas
queried for all patients transplanted atMCCbetween January 1, 2009
throughDecember 31, 2009. From a total 355 patients, we randomly
selected 200 autologous and allogeneic patients for evaluation.
The correlation between the calculated CrCl based on actual, ad-
justed, and ideal body weight and collected CrCl was determined.
Pearson correlation coefficients of log-transformed data are pre-
sented in Table 1.The magnitude of correlation was greatest for
CrCl based on ideal body weight and collected CrCl, and statistical
comparison between competing approaches for calculated CrCl (ac-Table 1. Pearson Correlation Coefficients, N 5 200
L_CrCl_Actual L_CrCl_Ideal L_CrCl_Adj L_Collected_CRCl
L_CrCl_Actual* 1.00000 0.81541 p < 0.0001 0.96953 p < 0.0001 0.60256 p < 0.0001
L_CrCl_Ideal^ 0.81541 p < 0.0001 1.00000 0.92888 p < 0.0001 0.71345 p < 0.0001
L_CrCl_Adj& 0.96953 p < 0.0001 0.92888 p < 0.0001 1.00000 0.67072 p < 0.0001
L_Collected_CRCl 0.60256 p < 0.0001 0.71345 p < 0.0001 0.67072 p < 0.0001 1.00000
L5 log-transformed data; *5 Creatinine clearance based off of actual body weight; ^5 Creatinine clearance based off of ideal body weight; &5 Cre-
atinine clearance based off of adjusted body weight.cording to actual, adjusted, or ideal body weight) confirmed that the
correlation between ideal bodyweight and collectedwas significantly
greater than that for either actual (p \ 0.0001) or adjusted (p \
0.0001).
These data indicate that ideal body weight-based calculated creat-
inine clearance most closely approximates collected creatinine clear-
ance. Based on these results, we recommend ideal body weight for
such calculations for dosing of conditioning chemotherapy and im-
mune suppressive agents following HCT.
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PHARMACY DRIVEN POSACONAZOLE THERAPEUTIC MONITORING IN
A LEUKEMIA AND BONE MARROW TRANSPLANT CENTER
Leech, M.1, LaPorte, J.1, Mihelic, R.1, Sanacore, M.1, Sizemore, C.1,
Zhang, X.2, Penland, P.1, Holland, H.K.2, Morris, L.E.2,
Solomon, S.R.2, Bashey, A.2 1Blood and Marrow Transplant Program,
Northside Hospital, Atlanta, GA; 2Blood and Marrow Transplant Group
of Georgia, Atlanta, GA
Objectives: Posaconazole (POS) is an extended-spectrum triazole
with proven efficacy for antifungal prophylaxis in patients (pts) un-dergoing HSCT or treatment of acute leukemia. The FDA recom-
mends a goal POS average serum drug concentration of .700 ng/
ml. We implemented a pharmacy-driven POS therapeutic monitor-
ing program. Our primary objective was to see if pharmacy interven-
tion can be helpful in optimizing attainment of therapeutic POS
levels.
Methods: Forty-eight steady-state plasma trough POS levels (33 in
HSCT pts, 15 in pts undergoing acute leukemia therapy) performed
after at least 7 days of administration were analyzed.
Results: POS levels were .700 ng/ml in 19/48 (40%) pts. Mean
POS level was 790 ng/ml (range 53- 2960), and median was 602
ng/ml. Of the 29 levels\700ng/ml, there were 26 dose modifica-
tions. POS was changed to another antifungal in 13 pts, POS was
discontinued in 2 pts, and dose was increased in 11 pts. Of the 11
increased doses, 8 follow up levels were drawn with 4 pts achiev-
ing a documented therapeutic level. POS was being used as pro-
phylaxis (starting dose 200mg TID) in 31 pts (65%) and
empirically (starting dose 400mg BID) in 17 pts (35%). The high-
est dose used was 400mg QID in one pt with documented fungal
infection.
GVHD was present in 16 of 33 HSCT pts (48%), and ten of the
pts had gut GVHD at the time of level. POS levels were .700ng/
mL in 6/16 (38%) and 2/10 (20%) of all GVHD and gut GVHD
pts, respectively, although this was not statistically signficant. Pro-
ton-pump inhibitor or H2 antagonist therapy (PPI/H2) was admin-
istered concurrently with 42/48 (88%) of levels, although the use of
these drugs had no apparent effect on therapeutic levels. Leukemia
pts were significantly less likely to achieve therapeutic POS levels
when compared to HSCT pts (27% vs 61%, p 5 0.029). Other
than treatment group, we found no other factors that correlated
with achieving therapeutic levels.
Conclusion: The pharmacy based implementation of POS thera-
peutic monitoring revealed that achievement of recommended
POS levels remains a challenge in an unselectedHSCT and leukemic
population. This program enabled documentation of compliance
and allowed an attempt at improvement of POS levels by dose adjust-
ment. Pharmacists counseled pts on ways to increase absorption by
taking with a high fat meal, nutritional supplement, or acidic carbon-
ated beverage, and by stopping their PPI/H2.470
REDUCED-DOSE MELPHALAN VS. STANDARD DOSE MELPHALAN FOR
AUTOLOGOUS STEM CELL TRANSPLANTATION: IS THERE A DIFFERENCE
IN OUTCOME?
Maewal, I.1, Gulbis, A.1, Champlin, R.E.2, Qazilbash, M.H.2 1MD
Anderson Cancer Center, Houston, TX; 2MD Anderson Cancer Center,
Houston, TX
Background: Based on the results of randomized phase III trials,
melphalan 200 mg/m2 IV (MEL 200) is considered the standard
preparative regimen for autologous hematopoietic stem cell trans-
plantation (auto-HCT) for multiple myeloma. However, reduced
doses of melphalan, 140 mg/m2 (MEL 140) or 180 mg/m2
(MEL 180), are often used in older patients or patients with renal
dysfunction.
Methods:The primary objective was to determine if there was a dif-
ference in toxicity, treatment-related mortality, response rate, pro-
gression-free survival or overall survival in patients that received
lower doses of melphalan for auto-HCT. From June 1, 1996 through
December 25, 2010, 1425 patients received auto-HCT at our insti-
tution. We identified 57 patients that received MEL 140 or 180 and
